Clinical Trials Directory

Trials / Unknown

UnknownNCT01530828

IRT in Infants With Intestinal Perforation

Immunoreactive Trypsinogen in Infants With Intestinal Perforation

Status
Unknown
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
Children's Hospitals and Clinics of Minnesota · Academic / Other
Sex
All
Age
1 Day – 16 Days
Healthy volunteers
Accepted

Summary

This study is designed to evaluate a novel tool to aid in the diagnosis of intestinal perforation in infants who are at high risk. Analysis of perforation rates of all infants in the three largest participating sites shows that the majority of infants with perforation will do so prior to day of life 21. This study will target the group of infants at highest risk for IP, those with birth weight less than 1000 grams, within the time frame most likely to capture the perforation. Hypothesis: An IRT value exists that can adequately differentiate premature infants with and without intestinal perforation in the first 3 weeks of life.

Detailed description

At least 300 infants age 1-16 days will be enrolled. IRT values will be obtained daily through day of life 21, if the infant is already having labs drawn that day. The primary outcomes will be intestinal perforation and/or death on or before day of life 21. Each patient will be followed until death or discharge. Discharge will be defined as the release of the infant to home. Infants who are transferred to another NICU may be followed if the receiving NICU is one of the investigational sites. Transfer includes the release of the infant to outside units or other units within the same hospital. The purpose of this follow up is to obtain serial IRT values through day of life 21.

Conditions

Timeline

Start date
2010-08-01
Primary completion
2013-09-01
Completion
2014-08-01
First posted
2012-02-10
Last updated
2013-08-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01530828. Inclusion in this directory is not an endorsement.